JP2023123627A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023123627A5 JP2023123627A5 JP2023101662A JP2023101662A JP2023123627A5 JP 2023123627 A5 JP2023123627 A5 JP 2023123627A5 JP 2023101662 A JP2023101662 A JP 2023101662A JP 2023101662 A JP2023101662 A JP 2023101662A JP 2023123627 A5 JP2023123627 A5 JP 2023123627A5
- Authority
- JP
- Japan
- Prior art keywords
- cdr
- pharmaceutical composition
- subject
- masp
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025072148A JP2025108730A (ja) | 2017-08-15 | 2025-04-24 | 造血幹細胞移植に関連する移植片対宿主病および／またはびまん性肺胞出血および／または静脈閉塞症を治療および／または予防するための方法 |
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762545864P | 2017-08-15 | 2017-08-15 | |
| US62/545,864 | 2017-08-15 | ||
| US201762574690P | 2017-10-19 | 2017-10-19 | |
| US62/574,690 | 2017-10-19 | ||
| US201862630756P | 2018-02-14 | 2018-02-14 | |
| US62/630,756 | 2018-02-14 | ||
| US201862637281P | 2018-03-01 | 2018-03-01 | |
| US62/637,281 | 2018-03-01 | ||
| PCT/US2018/046690 WO2019036460A1 (en) | 2017-08-15 | 2018-08-14 | METHODS OF TREATING AND / OR PREVENTING HOST GRAFT DISORDER AND / OR DIFFUSE ALVEOLAR HEMORRHAGE AND / OR VENO-OCCLUSIVE DISEASE ASSOCIATED WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION |
| JP2020508563A JP2020531452A (ja) | 2017-08-15 | 2018-08-14 | 造血幹細胞移植に関連する移植片対宿主病および／またはびまん性肺胞出血および／または静脈閉塞症を治療および／または予防するための方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020508563A Division JP2020531452A (ja) | 2017-08-15 | 2018-08-14 | 造血幹細胞移植に関連する移植片対宿主病および／またはびまん性肺胞出血および／または静脈閉塞症を治療および／または予防するための方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025072148A Division JP2025108730A (ja) | 2017-08-15 | 2025-04-24 | 造血幹細胞移植に関連する移植片対宿主病および／またはびまん性肺胞出血および／または静脈閉塞症を治療および／または予防するための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023123627A JP2023123627A (ja) | 2023-09-05 |
| JP2023123627A5 true JP2023123627A5 (https=) | 2024-02-09 |
Family
ID=65362042
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020508563A Pending JP2020531452A (ja) | 2017-08-15 | 2018-08-14 | 造血幹細胞移植に関連する移植片対宿主病および／またはびまん性肺胞出血および／または静脈閉塞症を治療および／または予防するための方法 |
| JP2023101662A Pending JP2023123627A (ja) | 2017-08-15 | 2023-06-21 | 造血幹細胞移植に関連する移植片対宿主病および／またはびまん性肺胞出血および／または静脈閉塞症を治療および／または予防するための方法 |
| JP2025072148A Pending JP2025108730A (ja) | 2017-08-15 | 2025-04-24 | 造血幹細胞移植に関連する移植片対宿主病および／またはびまん性肺胞出血および／または静脈閉塞症を治療および／または予防するための方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020508563A Pending JP2020531452A (ja) | 2017-08-15 | 2018-08-14 | 造血幹細胞移植に関連する移植片対宿主病および／またはびまん性肺胞出血および／または静脈閉塞症を治療および／または予防するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025072148A Pending JP2025108730A (ja) | 2017-08-15 | 2025-04-24 | 造血幹細胞移植に関連する移植片対宿主病および／またはびまん性肺胞出血および／または静脈閉塞症を治療および／または予防するための方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US11013772B2 (https=) |
| EP (1) | EP3668531A4 (https=) |
| JP (3) | JP2020531452A (https=) |
| KR (3) | KR102679441B1 (https=) |
| CN (3) | CN118436776A (https=) |
| AU (1) | AU2018318982B2 (https=) |
| BR (1) | BR112020003207A2 (https=) |
| CA (1) | CA3072940A1 (https=) |
| CL (3) | CL2020000384A1 (https=) |
| GE (2) | GEP20237541B (https=) |
| IL (3) | IL272674B2 (https=) |
| JO (1) | JOP20200021A1 (https=) |
| MA (1) | MA49915A (https=) |
| MX (3) | MX2020001728A (https=) |
| MY (1) | MY210026A (https=) |
| PH (1) | PH12020500276A1 (https=) |
| SG (1) | SG11202001014WA (https=) |
| TW (3) | TWI881481B (https=) |
| WO (1) | WO2019036460A1 (https=) |
| ZA (1) | ZA202407503B (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL311042B1 (en) | 2018-05-29 | 2026-04-01 | Omeros Corp | MASP-2 inhibitors and methods of use |
| US11584714B2 (en) | 2018-05-29 | 2023-02-21 | Omeros Corporation | MASP-2 inhibitors and methods of use |
| MX2022006334A (es) * | 2019-11-26 | 2022-06-22 | Omeros Corp | Metodos para tratar y/o prevenir el sindrome de neumonia idiopatica (ips) y/o el sindrome de fuga capilar (cls) y/o el sindrome de injerto (es) y/o la sobrecarga de fluidos (fo) asociados con el trasplante de celulas madre hematopoyeticas. |
| BR112022010895A2 (pt) | 2019-12-04 | 2022-09-06 | Omeros Corp | Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado à serina protease-2 associada à lectina de ligação ao manan |
| EP4069676A1 (en) | 2019-12-04 | 2022-10-12 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| IL293588B1 (en) | 2019-12-04 | 2026-04-01 | Omeros Corp | 3-Amino-1-methylpyrazin-2(H1)-one derivatives as MASP-2 inhibitors, compositions containing them and uses thereof |
| EP4069678A1 (en) | 2019-12-04 | 2022-10-12 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| CN116322670A (zh) * | 2020-07-22 | 2023-06-23 | 北京泰德制药股份有限公司 | 治疗造血干细胞移植后的移植物抗宿主病的方法 |
| CN113057142B (zh) * | 2021-03-30 | 2022-12-09 | 四川大学华西医院 | 一种视网膜内和/或视网膜下纤维化动物模型的构建方法 |
| TW202305010A (zh) * | 2021-04-25 | 2023-02-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗ｍａｓｐ２抗體、其抗原結合片段及醫藥用途 |
| US20230265215A1 (en) | 2021-12-10 | 2023-08-24 | Omeros Corporation | Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof |
| CN114532982A (zh) * | 2022-01-12 | 2022-05-27 | 高谋 | 评价干细胞系统移植调控补体活化作用的体系 |
| CN114686585B (zh) * | 2022-04-01 | 2023-06-30 | 中国人民解放军总医院 | Tmem65在预警和/或治疗高原病中的应用 |
| EP4626891A1 (en) | 2022-11-30 | 2025-10-08 | Omeros Corporation | Fused pyrimidines as masp-2 inhibitors |
| US20250122225A1 (en) | 2023-10-06 | 2025-04-17 | Omeros Corporation | Masp-2 inhibitors and methods of use |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4394370A (en) | 1981-09-21 | 1983-07-19 | Jefferies Steven R | Bone graft material for osseous defects and method of making same |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4526909A (en) | 1984-01-09 | 1985-07-02 | Regents Of The University Of California | Polymethylmethacrylate delivery system for bone morphogenetic protein |
| US4563489A (en) | 1984-02-10 | 1986-01-07 | University Of California | Biodegradable organic polymer delivery system for bone morphogenetic protein |
| JPH0662679B2 (ja) | 1985-06-21 | 1994-08-17 | 新田ゼラチン株式会社 | 組織親和性コラ−ゲンとその製法 |
| US5453566A (en) | 1986-03-28 | 1995-09-26 | Calgene, Inc. | Antisense regulation of gene expression in plant/cells |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| MC2115A1 (fr) | 1987-12-15 | 1991-07-05 | Gene Shears Pty Ltd | Ribozynes |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8822492D0 (en) | 1988-09-24 | 1988-10-26 | Considine J | Apparatus for removing tumours from hollow organs of body |
| US5211657A (en) | 1988-11-07 | 1993-05-18 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| EP0438803B1 (en) | 1990-01-26 | 1997-03-12 | Immunomedics, Inc. | Vaccines against cancer and infectious diseases |
| JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
| US5789573A (en) | 1990-08-14 | 1998-08-04 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2 |
| JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
| IL108367A0 (en) | 1993-01-27 | 1994-04-12 | Hektoen Inst For Medical Resea | Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US5856121A (en) | 1994-02-24 | 1999-01-05 | Case Western Reserve University | Growth arrest homebox gene |
| US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| JPH10510540A (ja) | 1994-12-12 | 1998-10-13 | オメロス メディカル システムズ，インコーポレーテッド | 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法 |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| US5739119A (en) | 1996-11-15 | 1998-04-14 | Galli; Rachel L. | Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA |
| JP2003505427A (ja) | 1999-07-21 | 2003-02-12 | オメロス コーポレイション | 疼痛、炎症および軟骨分解の抑制のための溶液および方法 |
| US6649592B1 (en) | 2000-01-14 | 2003-11-18 | Science & Technology Corporation @ Unm | Peptide inhibitors of LFA-1/ICAM-1 interaction |
| SG98393A1 (en) | 2000-05-19 | 2003-09-19 | Inst Materials Research & Eng | Injectable drug delivery systems with cyclodextrin-polymer based hydrogels |
| CN1697647A (zh) | 2002-02-01 | 2005-11-16 | 奥默罗斯公司 | 用于抑制疼痛,炎症和软骨退化的溶液及方法 |
| ES2601143T3 (es) | 2002-07-19 | 2017-02-14 | Omeros Corporation | Copolímeros tribloque biodegradables, métodos de síntesis de los mismos, e hidrogeles y biomateriales preparados a partir de los mismos |
| HUE024996T2 (en) | 2003-05-12 | 2016-01-28 | Helion Biotech Aps | Anti-MASP-2 antibodies |
| CN101065148A (zh) * | 2003-07-03 | 2007-10-31 | 奥索-麦克尼尔药品公司 | 结合补体级联抑制剂 |
| US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| EP1879610A1 (en) | 2005-05-06 | 2008-01-23 | Laboratoires Serono S.A. | Use of an immunoglobulin domain-containing cell surface recognition molecule for treating diseases |
| ES2688589T3 (es) | 2010-07-21 | 2018-11-05 | Eastern Virginia Medical School | Compuestos peptídicos para regular el sistema del complemento |
| US9644035B2 (en) * | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US20150166676A1 (en) * | 2011-04-08 | 2015-06-18 | Omeros Corporation | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation |
| HUE049154T2 (hu) * | 2011-05-04 | 2020-09-28 | Omeros Corp | Készítmények a MASP-2-függõ komplement-aktiválás gátlására |
| HK1218300A1 (zh) * | 2013-01-23 | 2017-02-10 | Musc Foundation For Research Development | 基於天然抗體的靶向結構體及其應用 |
| JP2016539919A (ja) * | 2013-10-17 | 2016-12-22 | オメロス コーポレーション | Ｍａｓｐ−２依存性補体活性化に関連した状態を治療するための方法 |
| WO2015187992A2 (en) * | 2014-06-05 | 2015-12-10 | The Regents Of The University Of Colorado, A Body Corporate | Map44 polypeptides and constructs based on natural antibodies and uses thereof |
| CA2988313A1 (en) * | 2015-06-08 | 2016-12-15 | Volution Immuno Pharmaceuticals Sa | Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease |
| AU2016354117B2 (en) * | 2015-11-09 | 2019-11-28 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
-
2018
- 2018-08-13 TW TW112136719A patent/TWI881481B/zh active
- 2018-08-13 TW TW114113955A patent/TW202529812A/zh unknown
- 2018-08-13 TW TW107128182A patent/TWI818919B/zh active
- 2018-08-14 WO PCT/US2018/046690 patent/WO2019036460A1/en not_active Ceased
- 2018-08-14 IL IL272674A patent/IL272674B2/en unknown
- 2018-08-14 KR KR1020207006893A patent/KR102679441B1/ko active Active
- 2018-08-14 JO JOP/2020/0021A patent/JOP20200021A1/ar unknown
- 2018-08-14 CN CN202410427006.0A patent/CN118436776A/zh active Pending
- 2018-08-14 IL IL315724A patent/IL315724A/en unknown
- 2018-08-14 EP EP18845831.9A patent/EP3668531A4/en active Pending
- 2018-08-14 IL IL315726A patent/IL315726A/en unknown
- 2018-08-14 CA CA3072940A patent/CA3072940A1/en active Pending
- 2018-08-14 JP JP2020508563A patent/JP2020531452A/ja active Pending
- 2018-08-14 CN CN201880052958.1A patent/CN111278449B/zh active Active
- 2018-08-14 SG SG11202001014WA patent/SG11202001014WA/en unknown
- 2018-08-14 GE GEAP201815297A patent/GEP20237541B/en unknown
- 2018-08-14 MX MX2020001728A patent/MX2020001728A/es unknown
- 2018-08-14 MA MA049915A patent/MA49915A/fr unknown
- 2018-08-14 KR KR1020247021113A patent/KR102863808B1/ko active Active
- 2018-08-14 AU AU2018318982A patent/AU2018318982B2/en active Active
- 2018-08-14 GE GEAP202315297A patent/GEAP202315297A/en unknown
- 2018-08-14 KR KR1020257031404A patent/KR20250150131A/ko active Pending
- 2018-08-14 MY MYPI2024000764A patent/MY210026A/en unknown
- 2018-08-14 CN CN202410427005.6A patent/CN118634322A/zh active Pending
- 2018-08-14 BR BR112020003207-7A patent/BR112020003207A2/pt unknown
- 2018-08-14 US US16/103,332 patent/US11013772B2/en active Active
-
2020
- 2020-02-06 PH PH12020500276A patent/PH12020500276A1/en unknown
- 2020-02-12 MX MX2024012815A patent/MX2024012815A/es unknown
- 2020-02-12 MX MX2024012816A patent/MX2024012816A/es unknown
- 2020-02-14 CL CL2020000384A patent/CL2020000384A1/es unknown
-
2021
- 2021-04-09 US US17/226,987 patent/US11896621B2/en active Active
-
2022
- 2022-01-25 CL CL2022000195A patent/CL2022000195A1/es unknown
- 2022-01-25 CL CL2022000194A patent/CL2022000194A1/es unknown
-
2023
- 2023-06-21 JP JP2023101662A patent/JP2023123627A/ja active Pending
- 2023-12-06 US US18/531,118 patent/US20240293465A1/en active Pending
-
2024
- 2024-10-02 ZA ZA2024/07503A patent/ZA202407503B/en unknown
-
2025
- 2025-04-24 JP JP2025072148A patent/JP2025108730A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023123627A5 (https=) | ||
| JP2021514973A5 (https=) | ||
| JP2011506483A5 (https=) | ||
| CN103298833B (zh) | β淀粉样蛋白结合蛋白 | |
| RU2008149918A (ru) | Антитела к nkg2a и их применения | |
| TW202115114A (zh) | 針對靶向ｂ細胞成熟抗原的多特異抗體之給藥方案及組合療法 | |
| JP2018527903A5 (https=) | ||
| JP2023544407A5 (https=) | ||
| MX2013009130A (es) | Tratamiento de la osteoartritis y del dolor. | |
| JP2023524149A5 (https=) | ||
| IL272674B2 (en) | Preparations for use in the treatment or prevention of graft-versus-graft disease or disseminated intravascular hemorrhage or veno-occlusive disease associated with hematopoietic stem cell transplantation | |
| TW201124427A (en) | IL-1 binding proteins | |
| JP2014503202A (ja) | ＴＮＦ−α結合性タンパク質 | |
| JP2023542290A5 (https=) | ||
| JP2023542289A5 (https=) | ||
| JP2024534602A5 (https=) | ||
| JP2022528721A5 (https=) | ||
| JP2023542291A5 (https=) | ||
| JP2023542092A5 (https=) | ||
| JP2022513386A5 (https=) | ||
| RU2008140947A (ru) | Антитела к egfl7 и способы их применения | |
| JP2023520771A5 (https=) | ||
| JP2022520107A5 (https=) | ||
| JP2024528877A5 (https=) | ||
| JP2024525870A5 (https=) |